Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine the safety, tolerability and Overall Response Rate (ORR) of pembrolizumab in each of the three cohorts listed below. Cohort 1: Subjects with relapsed/refractory classical Hodgkin Lymphoma who have failed to achieve a response, or progressed after auto stem cell transplant (auto-SCT) and have relapsed after treatment with or failed to respond to brentuximab vedotin. Cohort 2: Subjects with relapsed/refractory classical Hodgkin Lymphoma who were unable to achieve a complete or partial response to salvage chemotherapy and did not receive auto-SCT but have relapsed after treatment with or failed to respond to brentuximab vedotin. Cohort 3: Subjects with relapsed/refractory classical Hodgkin Lymphoma who have failed to achieve a response to or progressed after auto-SCT and have not received brentuximab vedotin. These subjects may or may not have received brentuximab vedotin as part of primary treatment or salvage therapy.
Inclusion criteria
- Hodgkin lymphoma